

ASX Announcement/Press Release | 30 October 2024
AdAlta Limited (ASX:1AD)

AdAlta to present at TSN's Emerging ASX Gems conference

AdAlta Limited (ASX:1AD) Chief Executive Officer & Managing Director Dr Tim Oldham will be presenting at The Stock Network (TSN) Emerging ASX Gems Investment Conference on Friday 1 November 2024.

In his presentation at this event, Dr Oldham will:

- Explain how AdAlta's i-body[®] drug discovery platform is creating next gen protein and cell therapies for debilitating diseases like fibrosis
- Provide an update on the development journey of current key drug candidate AD-214
- Explain the growth strategies being pursued by AdAlta's AdSolis and AdCella subsidiaries.

TSN Emerging ASX Gems Investment Conference Registration Details:

DATE: Friday 1 November 2024
TIME: 9AM - 12PM AEDT
FORMAT: The Stock Network YouTube Channel

Please register in advance using the following link:

<https://www.eventbrite.com/e/1059202325669?aff=oddtcreator>

After registering, you will receive a confirmation email containing information about joining the webinar.

Ends.

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries

The Capital Network
Julia Maguire
P: +61 2 8999 3699
E: julia@thecapitalnetwork.com.au

About AdAlta Limited

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody enabled protein and cell therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is extending Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. Preparation for Phase II clinical studies is also underway. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.


The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to codevelop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation ibody platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

To learn more, please visit: www.adalta.com.au

For more information

 Follow us on [Twitter](#)

 Follow us on [LinkedIn](#)

This ASX announcement has been authorised by the Board of AdAlta Limited (ASX:1AD)